In the first quarter of 2022, China continued its push for Cosmetic Supervision and Administration Regulation (CSAR) subsidiary regulations. Additionally, the Good Manufacturing Practices (GMP) regulation and adverse reaction monitoring regulation were finalized. With these updates, a new standard also was drafted for reviewing safety assessment reports.
In addition, the ASEAN region, South Korea and China, particularly Taiwan, made significant changes to ingredient lists, and essential regulatory updates were made in Indonesia. Following is an overview.
China: GMPs
On Jan. 7, 2022, China’s National Medical Products Administration (NMPA) published the finalized “Good Manufacturing Practices for Cosmetics,”1 which covers the basic requirements for cosmetic production quality management and all aspects of the cosmetic output and quality control.
By Winnie Xu – May 1st, 2022
Follow us on Linkedin!